Zsírmáj (MASLD/MASH): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• IDO1 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0

1999 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Subcellular Lipid Atlas: Decoding Organelle Identity with Targeted Lipid Profiling (LipID)

  Universitat Wien· Wien, Ausztria· EU contribution 1 500 000 EUR· until 2032. jún.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Metabolic Hepatoprotection to Enable Curative Cancer Therapy in Patients with Vulnerable Livers (SAFE-LIVER)

  Universitaet Bern· Bern, Svájc· EU contribution 150 000 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Epigenomic Liquid Biopsy for Early Detection and Monitoring of Metabolic Dysfunction-Associated Steatohepatitis (cfChIP-MASH)

  The Hebrew University of Jerusalem· Jerusalem, Izrael· EU contribution 150 000 EUR· until 2028. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Crossing borders of liver and adipose tissue (mis)communication: a novel translational approach to study molecular mechanisms and targets in metabolic dysfunction-associated steatotic liver disease (XB-LIVAT)

  Fondazione Italiana Fegato E.t.s.· Trieste, Olaszország· EU contribution 193 643 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploring the impact of Time-Restricted Eating and Exercise interventions on Gut microbiome of patients with hepatic steatosis and obesity – TREEGut

  Universidad de Granada· Granada, Spanyolország· EU contribution 194 075 EUR· until 2027. dec.· 2 countries

5 of 22 running projects, newest first. Listed amounts together: 71,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

  NCT03587831· University of Minnesota· Frissítve: 2026. szept. 30.

  “Study has been terminated due to poor recruitment and early evidence of futility”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  NAFLD in Adolescents and Young Adults With PCOS

  NCT02506946· Columbia University· Frissítve: 2026. szept. 30.

  “Lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Non-alcoholic Steatohepatitis Registry Platform Study

  NCT06123858· AstraZeneca· Frissítve: 2026. júl. 29.

  “Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Frissítve: 2026. júl. 13.

  “no grant approved”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Assessment of Fatty Liver With Thermo-acoustic Device

  NCT04302051· Medical College of Wisconsin· Frissítve: 2026. júl. 10.

  “The sponsor withdrew from the study”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Galectin Therapeutics Inc.· Frissítve: 2026. jún. 30.

  “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Prevention of NAFLD in Hispanic Children

  NCT05292352· Emory University· Frissítve: 2026. jún. 2.

  “Study was terminated due to a lack of funding. Data collection was completed for 12-month outcomes; however, funding limitations prevented follow-up for longer timeframes, and some outcomes were not fully collected.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

  NCT06939816· Enyo Pharma· Frissítve: 2026. ápr. 23.

  “Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

  NCT06007651· Eli Lilly and Company· Frissítve: 2026. ápr. 13.

  “Participants were not dosed in Part B as per the protocol.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  FCI Effectiveness in NAFLD Stratification

  NCT05827432· NHS Grampian· Frissítve: 2026. ápr. 1.

  “Funding period ended.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· GlaxoSmithKline· Forrás

• ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Boehringer Ingelheim· Forrás

• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)

  NCT07933328· Regeneron Pharmaceuticals· Forrás

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Boehringer Ingelheim· Forrás

• Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects With Type 2 Diabetes

  NCT06895018· Federico II University· Forrás

• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  NCT05519475· Regeneron Pharmaceuticals· Forrás

• Isocaloric Navy-Bean Substitution in Adults With MASLD

  NCT07730853· Icahn School of Medicine at Mount Sinai· Forrás

• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Regeneron Pharmaceuticals· Forrás

• A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07701993· GlaxoSmithKline· Forrás

• A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

  NCT07358546· GlaxoSmithKline· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 66
• Metabolomics 104
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 103
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 172
• Genome-Wide Association Study 49

• Nε-(Carboxymethyl)lysine induces mitochondrial stress, inflammatory activation, and fibrogenic remodelling in multicellular human liver organoids.

  Pharmacol Res, 2026. szept.

• Prime editing models the MTARC1 A165T variant in human liver organoids, demonstrating reduced steatosis, inflammation, and fibrosis.

  Hepatol Commun, 2026. szept.

• A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing.

  PLoS One, 2026. aug.

• MASH Background Confers Enhanced Disease Susceptibility and Acetaminophen Toxicity in iPSC-Derived Liver Organoids.

  Adv Sci (Weinh), 2026. júl.

• Application of Multilineage Human Liver Organoids in Disease Modelling, Drug Testing and Genetic Intervention.

  Liver Int, 2026. júl.

• Hepatoprotective effects of the branched-chain fatty acids 12-methylmyristic and 13-methylmyristic against palmitate-induced lipotoxicity.

  Biomed Pharmacother, 2026. jún.

• S100A10-ANXA2 tetramer inhibition hampers hepatic stellate cell activation in human MASLD organoids.

  EMBO Mol Med, 2026. jún.

• Profiling of extracellular vesicles from primary hepatocytes, organoids, and mash patients identifies cell injury-specific signatures.

  Sci Rep, 2026. jún.

• Organoid models reveal mechanistic connections and sirolimus efficacy in liver-vascular steatosis and foam cell formation.

  Atherosclerosis, 2026. máj.

• New approach methodologies to model liver fibrosis in metabolic dysfunction-associated steatohepatitis.

  BMB Rep, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.